MAPK3 and melanoma: Separate use of inhibitors: U0126 (ERK1/2) or everolimus (mTOR) reduced melanoma cell invasion by approximately 21–25% (p < 0.005), whereas treatment with LY294002 (PI3K) reduced it by only about 15% (p < 0.005).